Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer—Is it indicated?

Ashley N. Krepline, Kathleen K. Christians, Ben George, Paul S. Ritch, Beth A. Erickson, Parag Tolat, Douglas B. Evans, Susan Tsai

Research output: Contribution to journalArticle

Abstract

Purpose: To describe venous thromboembolism (VTE) rates in patients with pancreatic cancer (PC) during neoadjuvant therapy. Methods: Factors associated with VTE were evaluated using multivariable logistic regression modeling in patients with resectable and BLR PC treated with neoadjuvant therapy between 2009 and 2014. Results: Prevalent VTEs were detected in 13 (5%) of the 260 patients. Incident VTEs were detected in 26 patients (10%); 9 (8%) of the 109 resectable and 17 (11%) of the 151 BLR patients (P = 0.53). Of the 26 incident events, 9 (35%) were PEs, 9 (35%) were extremity DVTs, and 8 (31%) involved the SMV/PV. VTEs were catheter-related in 7 (27%) of the 26 patients. Rh(D) antigen positivity was associated with a decreased risk of incident VTE (OR:0.32, 95%CI:0.11–0.85, P = 0.02). Completion of neoadjuvant therapy to include surgery occurred in 176 (75%) of the 234 patients without incident VTE as compared to 14 (54%) of the 26 patients with incident VTE (P = 0.02). The median survival for all 260 patients was 24.3 months: 17.0 months versus 24.6 months for patients who did and did not develop incident VTE during neoadjuvant therapy (P = 0.11). Conclusions: Patients with localized PC who receive neoadjuvant therapy are at significant risk of VTE and thromboprophylaxis may be warranted. J. Surg. Oncol. 2016;114:581–586.

Original languageEnglish (US)
Pages (from-to)581-586
Number of pages6
JournalJournal of Surgical Oncology
Volume114
Issue number5
DOIs
StatePublished - Oct 1 2016

Keywords

  • neoadjuvant therapy
  • pancreatic cancer
  • venous thromboembolism

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer—Is it indicated?'. Together they form a unique fingerprint.

  • Cite this

    Krepline, A. N., Christians, K. K., George, B., Ritch, P. S., Erickson, B. A., Tolat, P., Evans, D. B., & Tsai, S. (2016). Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer—Is it indicated? Journal of Surgical Oncology, 114(5), 581-586. https://doi.org/10.1002/jso.24361